MX2024014419A - Peptidos y metodos para usar en el tratamiento del dolor - Google Patents

Peptidos y metodos para usar en el tratamiento del dolor

Info

Publication number
MX2024014419A
MX2024014419A MX2024014419A MX2024014419A MX2024014419A MX 2024014419 A MX2024014419 A MX 2024014419A MX 2024014419 A MX2024014419 A MX 2024014419A MX 2024014419 A MX2024014419 A MX 2024014419A MX 2024014419 A MX2024014419 A MX 2024014419A
Authority
MX
Mexico
Prior art keywords
peptides
methods
pain treatment
pain
treatment
Prior art date
Application number
MX2024014419A
Other languages
English (en)
Spanish (es)
Inventor
Abdelaziz Moqrich
Stéphane Gaillard
Original Assignee
Tafalgie Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tafalgie Therapeutics filed Critical Tafalgie Therapeutics
Publication of MX2024014419A publication Critical patent/MX2024014419A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024014419A 2022-05-25 2024-11-21 Peptidos y metodos para usar en el tratamiento del dolor MX2024014419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22305773 2022-05-25
PCT/EP2023/064091 WO2023227731A1 (en) 2022-05-25 2023-05-25 Peptides and methods for use in treating pain

Publications (1)

Publication Number Publication Date
MX2024014419A true MX2024014419A (es) 2024-12-06

Family

ID=81975215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024014419A MX2024014419A (es) 2022-05-25 2024-11-21 Peptidos y metodos para usar en el tratamiento del dolor

Country Status (12)

Country Link
US (1) US20250213654A1 (cg-RX-API-DMAC7.html)
EP (1) EP4531886A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025519127A (cg-RX-API-DMAC7.html)
KR (1) KR20250017221A (cg-RX-API-DMAC7.html)
CN (1) CN119730868A (cg-RX-API-DMAC7.html)
AR (1) AR129441A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023275937A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253053A1 (cg-RX-API-DMAC7.html)
IL (1) IL317048A (cg-RX-API-DMAC7.html)
MX (1) MX2024014419A (cg-RX-API-DMAC7.html)
TW (1) TW202409064A (cg-RX-API-DMAC7.html)
WO (1) WO2023227731A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
CN103382220A (zh) * 2012-05-03 2013-11-06 北京大学 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Also Published As

Publication number Publication date
AR129441A1 (es) 2024-08-28
IL317048A (en) 2025-01-01
AU2023275937A1 (en) 2024-12-12
KR20250017221A (ko) 2025-02-04
CA3253053A1 (en) 2023-11-30
CN119730868A (zh) 2025-03-28
TW202409064A (zh) 2024-03-01
WO2023227731A1 (en) 2023-11-30
EP4531886A1 (en) 2025-04-09
JP2025519127A (ja) 2025-06-24
US20250213654A1 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
PY2126213A (es) Compuestos y métodos para el tratamiento de covid-19
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
CO2024007220A2 (es) Compuestos que contienen heteroátomos y usos de estos
MX2023007162A (es) Macrociclos y sus usos.
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
CO2022000481A2 (es) Inhibidores de enzimas
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CL2023002549A1 (es) Ciertos compuestos de pladienolida y métodos de uso (divisional).
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
BR112022025551A2 (pt) Tratamento de disfunção atrial
CL2023000061A1 (es) Macrociclos y su uso
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
MX2024012368A (es) Terapia combinada para el tratamiento del cancer
CO2024017693A2 (es) Regímenes de dosis para tratamiento de infección de dengue
CL2024002627A1 (es) Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor.
MX2025014063A (es) Inhibidores de expresion y/o funcion
MX2022001450A (es) Metodo de tratamiento del cancer.
MX2024007301A (es) Peptidos y metodos para usar en el tratamiento del dolor.
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.
CO2023007839A2 (es) Compuestos y composiciones de moléculas pequeñas